The global demand for Ineffective Esophageal Motility Treatment Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period of 2022-2028.
Ineffective esophageal motility (IEM) is a medical condition in which the patient suffers from dysphagia (swallowing difficulty) and reflux. The causes of (IEM) include old age, diabetes, acid reflux, scleroderma, Parkinson's disease, achalasia, polymyositis amyotrophic lateral sclerosis. The IEM symptoms include difficulty in eating, heartburn, cough, excessive throat mucus, the sensation of a lump in the throat, and regurgitation. The proper diagnosis and treatment of IEM are essential as traditional anti-reflux medicines do not improve the condition. IEM treatment plan includes relaxation of lower esophageal sphincter (LES) muscles by proper medication or relieving the physiologic blockage at LES level by the surgical or endoscopic procedure. The other treatment option includes pharmacologic therapy.
Market Dyanamics
The global IEM treatment market is growing fast owing to the increasing geriatric population and increased prevalence of IEM & gastroesophageal reflux. Moreover, factors such as increasing R & D in IEM and other related medical conditions and advancement in treatment procedures such as radiofrequency stimulation of LES muscles are boosting the market. Growing adoption for minimally invasive treatments and drug-based treatments is further propelling the global market.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each segment in the global market of ineffective esophageal motility treatment.
Market Segmentation
This section of the ineffective esophageal motility treatment market report provides detailed data on the segments by analyzing them geographically, thereby assisting the strategist in identifying the target demographics for the respective product or service.
By Product
- Devices (Reflux Management Systems , Endoscopic Pain Modulators,Endostaplers,Radiofrequency (RF) Ablation Devices,Myotomy Devices)
- Drugs (H2 Receptor Antagonists,Antacids,Proton Pump Inhibitors,Dopamine Antagonists,Prokinetic Agents,Calcium Channel Blockers)
By Indication
- Dysphagia
- GERD
- Burning Chest Pain
- Achalasia
By End User
- Institutional Sales
- Hospitals
- Ambulatory Surgical Centers
- Retail Sales
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for ineffective esophageal motility treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Ineffective Esophageal Motility Treatment Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the ineffective esophageal motility treatment market include Johnson & Johnson, Mylan Pharmaceutical, MediGus Ltd., Torax Medical, Medtronic plc., AstraZeneca plc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Bayer AGS. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.